NFL Biosciences Initiates €3 Million Fundraising Through Capital Increase

NFL Biosciences, a French biopharmaceutical firm specializing in addiction treatment drugs, has announced a capital increase to raise approximately €3 million. This fundraising involves issuing new shares targeted at both professional and retail investors, with the latter being able to participate via the PrimaryBid platform. The offer price is set at €2.05 per new share, reflecting a 20.23% discount from the April 11 closing price. This move aims to finance the Phase 3 clinical trial of NFL-101, a smoking cessation aid, and advance the development of NFL-301 for alcohol consumption reduction.

The company outlines that the capital will specifically support the industrial scaling of NFL-101 to meet the Phase 3 trial requirements and ensure the drug's production matches that of commercial batches. Additionally, funds will be directed to the preliminary stages of NFL-301 development, following dialogue with the FDA. NFL Biosciences aims to bolster its position in the addiction treatment market with these botanical drug candidates.

The fundraising round splits between a reserved offer for professional investors closing on April 12, and a public offering for retail investors ending on April 11. This strategic financial move is designed to extend NFL Biosciences' cash horizon into the third quarter of 2025, alongside pursuing non-dilutive financing. The success of the fundraising is crucial for advancing the company's innovative treatment solutions to addressing global addiction challenges.